Fifty 410 Health Review

What Fifty 410 Health charges

• Semaglutide: $199/mo — per month on the pay-as-you-go option, billed as a single one-month total
• Tirzepatide: $133 — restated as $133 a month but billed $399 once for three months; the monthly tab on this page renders no figure
• Tirzepatide: $166 — restated as $166 a month but billed $499 once for three months
• Tirzepatide: $183 — restated as $183 a month but billed $549 once for three months

The letter names this seller's own website

The February 2026 letter opens by citing the address of this site, and its recipient block names the operating company trading as Fifty 410, a street address in Prosper, Texas, and the mail account the site publishes as its contact.

That is confirmation from the document itself rather than a name that happened to match a row in a table.

The letter is dated and it is about this seller, not about the drug class in general.

The pricing pages are reachable only through the sitemap

Neither the semaglutide pricing page nor the tirzepatide pricing page is linked from the homepage a reader lands on.

Both were found by reading the sitemap, and every figure recorded here comes from those two pages.

A crawl that follows only the site's own links returns no price at all, which is exactly the shape that produces a false claim that a seller publishes nothing.

Tirzepatide is priced by dose tier, and only in three-month blocks

Three tiers are published — a clinician-guided starting dose, a mid-range dose and a high dose — each restated as a monthly rate but billed once for three months.

A monthly tab exists on that same page and renders no figure at all, so only the three-month tiers are visible text and only those are recorded.

Semaglutide is different: it has a pay-as-you-go option billed as a single one-month total, with the provider consultation and the shipping stated as included.

What it states plainly, in its own words

It writes that "Compounded medications are prepared by independently licensed compounding pharmacies pursuant to patient-specific prescriptions in compliance with applicable provisions of Section 503A of the Federal Food, Drug, and Cosmetic Act, as well as state pharmacy laws", and adds that "Compounded semaglutide and compounded tirzepatide are not FDA-approved."

It also puts lab work on the reader: "Obtaining necessary lab work or diagnostic testing as directed by your Provider."

Its NAD+, sermorelin, glutathione and methylene blue products are labelled coming soon and carry no price, so nothing is recorded for any of them.

FDA disclosure

Fifty 410 Health received an FDA warning letter issued February 2026. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.

How we verified this

• Found both pricing pages in the sitemap after confirming neither is reachable from the homepage's own links, and read each one in full.
• Confirmed the tirzepatide monthly tab renders no figure, and recorded only the three-month tiers, each with its single charge kept beside the restated rate.
• Read the compounding statement and the lab-work sentence from the seller's own legal pages rather than from any summary of them.
• Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
• Confirmed the February 2026 federal warning letter from its own opening line, which names the seller's website, and from a recipient block carrying the operating company, its Prosper, Texas street address and the contact mail account the site publishes.